Israeli stocks plummet in wake of Hizbullah attack

July 12, 2006 16:07


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

In the wake of the latest violence on the Lebanese border, the TA-25 collapsed Wednesday, sliding 32.75 points to 784 in afternoon trade - a drop of 4% - making the benchmark index the biggest decliner of all global indices. Heaviest fallers were banking and real estate stocks, with IDB Holdings and Africa Israel both suffering drops of almost 7%. The broader TA-100 index fell 4.24%, down 35 points at 796.5. The shekel was also hard hit, trading down 1% at 4.43 to the dollar. "We know from previous experience that security crises [such as these] make clients less likely to invest in long-term products such as shares or property", said Rami Sasson, CEO of Bank Adanim, indicating that this fear was behind investors' decision to pull their money out of the stock market.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection